Skip to main content
Top
Published in: Trials 1/2022

Open Access 01-12-2022 | Stroke | Methodology

Optimizing a Bayesian hierarchical adaptive platform trial design for stroke patients

Authors: Guangyi Gao, Byron J. Gajewski, Jo Wick, Jonathan Beall, Jeffrey L. Saver, Caitlyn Meinzer, the STEP-STONE Executive Committee

Published in: Trials | Issue 1/2022

Login to get access

Abstract

Background

Platform trials are well-known for their ability to investigate multiple arms on heterogeneous patient populations and their flexibility to add/drop treatment arms due to efficacy/lack of efficacy. Because of their complexity, it is important to develop highly optimized, transparent, and rigorous designs that are cost-efficient, offer high statistical power, maximize patient benefit, and are robust to changes over time.

Methods

To address these needs, we present a Bayesian platform trial design based on a beta-binomial model for binary outcomes that uses three key strategies: (1) hierarchical modeling of subgroups within treatment arms that allows for borrowing of information across subgroups, (2) utilization of response-adaptive randomization (RAR) schemes that seek a tradeoff between statistical power and patient benefit, and (3) adjustment for potential drift over time. Motivated by a proposed clinical trial that aims to find the appropriate treatment for different subgroup populations of ischemic stroke patients, extensive simulation studies were performed to validate the approach, compare different allocation rules, and study the model operating characteristics.

Results and conclusions

Our proposed approach achieved high statistical power and good patient benefit and was also robust against population drift over time. Our design provided a good balance between the strengths of both the traditional RAR scheme and fixed 1:1 allocation and may be a promising choice for dichotomous outcomes trials investigating multiple subgroups.
Appendix
Available only for authorised users
Literature
1.
go back to reference Park JJH, Siden E, Zoratti MJ, Dron L, Harari O, Singer J, et al. Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols. Trials. 2019;20(1):572.PubMedPubMedCentralCrossRef Park JJH, Siden E, Zoratti MJ, Dron L, Harari O, Singer J, et al. Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols. Trials. 2019;20(1):572.PubMedPubMedCentralCrossRef
2.
go back to reference Woodcock J, LaVange LM. Master protocols to study multiple therapies, multiple diseases, or both. N Engl J Med. 2017;377(1):62–70.PubMedCrossRef Woodcock J, LaVange LM. Master protocols to study multiple therapies, multiple diseases, or both. N Engl J Med. 2017;377(1):62–70.PubMedCrossRef
3.
go back to reference Parmar MK, Sydes MR, Cafferty FH, Choodari-Oskooei B, Langley RE, Brown L, et al. Testing many treatments within a single protocol over 10 years at MRC Clinical Trials Unit at UCL: multi-arm, multi-stage platform, umbrella and basket protocols. Clin Trials. 2017;14(5):451–61.PubMedPubMedCentralCrossRef Parmar MK, Sydes MR, Cafferty FH, Choodari-Oskooei B, Langley RE, Brown L, et al. Testing many treatments within a single protocol over 10 years at MRC Clinical Trials Unit at UCL: multi-arm, multi-stage platform, umbrella and basket protocols. Clin Trials. 2017;14(5):451–61.PubMedPubMedCentralCrossRef
4.
go back to reference Bateman RJ, Benzinger TL, Berry S, Clifford DB, Duggan C, Fagan AM, et al. The DIAN-TU Next Generation Alzheimer’s prevention trial: adaptive design and disease progression model. Alzheimers Dement. 2017;13(1):8–19.PubMedCrossRef Bateman RJ, Benzinger TL, Berry S, Clifford DB, Duggan C, Fagan AM, et al. The DIAN-TU Next Generation Alzheimer’s prevention trial: adaptive design and disease progression model. Alzheimers Dement. 2017;13(1):8–19.PubMedCrossRef
5.
go back to reference Alexander BM, Ba S, Berger MS, Berry DA, Cavenee WK, Chang SM, et al. Adaptive global innovative learning environment for glioblastoma: GBM AGILE. Clin Cancer Res. 2018;24(4):737–43.PubMedCrossRef Alexander BM, Ba S, Berger MS, Berry DA, Cavenee WK, Chang SM, et al. Adaptive global innovative learning environment for glioblastoma: GBM AGILE. Clin Cancer Res. 2018;24(4):737–43.PubMedCrossRef
6.
go back to reference Park JW, Liu MC, Yee D, Yau C, van’t Veer LJ, Symmans WF, et al. Adaptive randomization of neratinib in early breast cancer. N Engl J Med. 2016;375(1):11–22.PubMedPubMedCentralCrossRef Park JW, Liu MC, Yee D, Yau C, van’t Veer LJ, Symmans WF, et al. Adaptive randomization of neratinib in early breast cancer. N Engl J Med. 2016;375(1):11–22.PubMedPubMedCentralCrossRef
7.
go back to reference Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJ. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther. 2009;86(1):97–100.PubMedCrossRef Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJ. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther. 2009;86(1):97–100.PubMedCrossRef
8.
go back to reference Saville BR, Berry SM. Efficiencies of platform clinical trials: a vision of the future. Clin Trials. 2016;13(3):358–66.PubMedCrossRef Saville BR, Berry SM. Efficiencies of platform clinical trials: a vision of the future. Clin Trials. 2016;13(3):358–66.PubMedCrossRef
9.
go back to reference Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, et al. Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study. J Clin Oncol. 2018;36(6):536–42.PubMedCrossRef Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, et al. Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study. J Clin Oncol. 2018;36(6):536–42.PubMedCrossRef
10.
go back to reference Li BT, Shen R, Buonocore D, Olah ZT, Ni A, Ginsberg MS, et al. Ado-trastuzumab emtansine for patients with HER2-mutant lung cancers: results from a phase II basket trial. J Clin Oncol. 2018;36(24):2532–7.PubMedPubMedCentralCrossRef Li BT, Shen R, Buonocore D, Olah ZT, Ni A, Ginsberg MS, et al. Ado-trastuzumab emtansine for patients with HER2-mutant lung cancers: results from a phase II basket trial. J Clin Oncol. 2018;36(24):2532–7.PubMedPubMedCentralCrossRef
11.
go back to reference Schoffski P, Sufliarsky J, Gelderblom H, Blay JY, Strauss SJ, Stacchiotti S, et al. Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial. Lancet Respir Med. 2018;6(6):431–41.PubMedCrossRef Schoffski P, Sufliarsky J, Gelderblom H, Blay JY, Strauss SJ, Stacchiotti S, et al. Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial. Lancet Respir Med. 2018;6(6):431–41.PubMedCrossRef
12.
go back to reference Simon R. Critical review of umbrella, basket, and platform designs for oncology clinical trials. Clin Pharmacol Ther. 2017;102(6):934–41.PubMedCrossRef Simon R. Critical review of umbrella, basket, and platform designs for oncology clinical trials. Clin Pharmacol Ther. 2017;102(6):934–41.PubMedCrossRef
13.
go back to reference Kim ES, Herbst RS, Wistuba II, Lee JJ, Blumenschein GR Jr, Tsao A, et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov. 2011;1(1):44–53.PubMedPubMedCentralCrossRef Kim ES, Herbst RS, Wistuba II, Lee JJ, Blumenschein GR Jr, Tsao A, et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov. 2011;1(1):44–53.PubMedPubMedCentralCrossRef
14.
go back to reference Herbst RS, Gandara DR, Hirsch FR, Redman MW, LeBlanc M, Mack PC, et al. Lung Master Protocol (Lung-MAP)-a biomarker-driven protocol for accelerating development of therapies for squamous cell lung cancer: SWOG S1400. Clin Cancer Res. 2015;21(7):1514–24.PubMedPubMedCentralCrossRef Herbst RS, Gandara DR, Hirsch FR, Redman MW, LeBlanc M, Mack PC, et al. Lung Master Protocol (Lung-MAP)-a biomarker-driven protocol for accelerating development of therapies for squamous cell lung cancer: SWOG S1400. Clin Cancer Res. 2015;21(7):1514–24.PubMedPubMedCentralCrossRef
15.
go back to reference Papadimitrakopoulou V, Lee JJ, Wistuba II, Tsao AS, Fossella FV, Kalhor N, et al. The BATTLE-2 study: a biomarker-integrated targeted therapy study in previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol. 2016;34(30):3638–47.PubMedPubMedCentralCrossRef Papadimitrakopoulou V, Lee JJ, Wistuba II, Tsao AS, Fossella FV, Kalhor N, et al. The BATTLE-2 study: a biomarker-integrated targeted therapy study in previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol. 2016;34(30):3638–47.PubMedPubMedCentralCrossRef
16.
go back to reference Albers GW, Marks MP, Kemp S, Christensen S, Tsai JP, Ortega-Gutierrez S, et al. Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging. New England J Med. 2018;378(8):708–18.CrossRef Albers GW, Marks MP, Kemp S, Christensen S, Tsai JP, Ortega-Gutierrez S, et al. Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging. New England J Med. 2018;378(8):708–18.CrossRef
17.
go back to reference Berkhemer OA, Fransen PS, Beumer D, Van Den Berg LA, Lingsma HF, Yoo AJ, et al. A randomized trial of intraarterial treatment for acute ischemic stroke. Engl J Med. 2015;372:11–20.CrossRef Berkhemer OA, Fransen PS, Beumer D, Van Den Berg LA, Lingsma HF, Yoo AJ, et al. A randomized trial of intraarterial treatment for acute ischemic stroke. Engl J Med. 2015;372:11–20.CrossRef
18.
go back to reference Campbell BC, Mitchell PJ, Kleinig TJ, Dewey HM, Churilov L, Yassi N, et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection. New England J Med. 2015;372(11):1009–18.CrossRef Campbell BC, Mitchell PJ, Kleinig TJ, Dewey HM, Churilov L, Yassi N, et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection. New England J Med. 2015;372(11):1009–18.CrossRef
19.
go back to reference Goyal M, Demchuk AM, Menon BK, Eesa M, Rempel JL, Thornton J, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. New England J Med. 2015;372(11):1019–30.CrossRef Goyal M, Demchuk AM, Menon BK, Eesa M, Rempel JL, Thornton J, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. New England J Med. 2015;372(11):1019–30.CrossRef
20.
go back to reference Jovin TG, Chamorro A, Cobo E, de Miquel MA, Molina CA, Rovira A, et al. Thrombectomy within 8 hours after symptom onset in ischemic stroke. New England J Med. 2015;372(24):2296–306.CrossRef Jovin TG, Chamorro A, Cobo E, de Miquel MA, Molina CA, Rovira A, et al. Thrombectomy within 8 hours after symptom onset in ischemic stroke. New England J Med. 2015;372(24):2296–306.CrossRef
21.
go back to reference Mocco J, Zaidat OO, von Kummer R, Yoo AJ, Gupta R, Lopes D, et al. Aspiration thrombectomy after intravenous alteplase versus intravenous alteplase alone. Stroke. 2016;47(9):2331–8.PubMedCrossRef Mocco J, Zaidat OO, von Kummer R, Yoo AJ, Gupta R, Lopes D, et al. Aspiration thrombectomy after intravenous alteplase versus intravenous alteplase alone. Stroke. 2016;47(9):2331–8.PubMedCrossRef
22.
go back to reference Nogueira RG, Jadhav AP, Haussen DC, Bonafe A, Budzik RF, Bhuva P, et al. Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. New England J Med. 2018;378(1):11–21.CrossRef Nogueira RG, Jadhav AP, Haussen DC, Bonafe A, Budzik RF, Bhuva P, et al. Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. New England J Med. 2018;378(1):11–21.CrossRef
23.
go back to reference Saver JL, Goyal M, Bonafe A, Diener H-C, Levy EI, Pereira VM, et al. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. New England J Med. 2015;372(24):2285–95.CrossRef Saver JL, Goyal M, Bonafe A, Diener H-C, Levy EI, Pereira VM, et al. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. New England J Med. 2015;372(24):2285–95.CrossRef
24.
go back to reference Muir KW, Ford GA, Messow C-M, Ford I, Murray A, Clifton A, et al. Endovascular therapy for acute ischaemic stroke: the Pragmatic Ischaemic Stroke Thrombectomy Evaluation (PISTE) randomised, controlled trial. J Neurol Neurosurg Psychiatry. 2017;88(1):38–44.PubMedCrossRef Muir KW, Ford GA, Messow C-M, Ford I, Murray A, Clifton A, et al. Endovascular therapy for acute ischaemic stroke: the Pragmatic Ischaemic Stroke Thrombectomy Evaluation (PISTE) randomised, controlled trial. J Neurol Neurosurg Psychiatry. 2017;88(1):38–44.PubMedCrossRef
27.
go back to reference Berry DA. The Brave New World of clinical cancer research: adaptive biomarker-driven trials integrating clinical practice with clinical research. Mol Oncol. 2015;9(5):951–9.PubMedPubMedCentralCrossRef Berry DA. The Brave New World of clinical cancer research: adaptive biomarker-driven trials integrating clinical practice with clinical research. Mol Oncol. 2015;9(5):951–9.PubMedPubMedCentralCrossRef
28.
go back to reference Berry SM, Connor JT, Lewis RJ. The platform trial: an efficient strategy for evaluating multiple treatments. JAMA. 2015;313(16):1619–20.PubMedCrossRef Berry SM, Connor JT, Lewis RJ. The platform trial: an efficient strategy for evaluating multiple treatments. JAMA. 2015;313(16):1619–20.PubMedCrossRef
29.
30.
go back to reference Schnell PM, Tang Q, Offen WW, Carlin BP. A Bayesian credible subgroups approach to identifying patient subgroups with positive treatment effects. Biometrics. 2016;72(4):1026–36.PubMedPubMedCentralCrossRef Schnell PM, Tang Q, Offen WW, Carlin BP. A Bayesian credible subgroups approach to identifying patient subgroups with positive treatment effects. Biometrics. 2016;72(4):1026–36.PubMedPubMedCentralCrossRef
31.
go back to reference Zang Y, Guo B, Han Y, Cao S, Zhang C. A Bayesian adaptive marker-stratified design for molecularly targeted agents with customized hierarchical modeling. Stat Med. 2019;38(15):2883–96.PubMedCrossRef Zang Y, Guo B, Han Y, Cao S, Zhang C. A Bayesian adaptive marker-stratified design for molecularly targeted agents with customized hierarchical modeling. Stat Med. 2019;38(15):2883–96.PubMedCrossRef
34.
go back to reference Cheng Y, Berry DA. Optimal adaptive randomized designs for clinical trials. Biometrika. 2007;94(3):673–89.CrossRef Cheng Y, Berry DA. Optimal adaptive randomized designs for clinical trials. Biometrika. 2007;94(3):673–89.CrossRef
36.
go back to reference Hu F, Rosenberger WF. The theory of response-adaptive randomization in clinical trials. Hoboken: Wiley; 2006. Hu F, Rosenberger WF. The theory of response-adaptive randomization in clinical trials. Hoboken: Wiley; 2006.
37.
go back to reference Thall PF, Fox PS, Wathen JK. Some caveats for outcome adaptive randomization in clinical trials. Modern adaptive randomized clinical trials: statistical and practical aspects: Chapman and Hall/CRC; 2015. p. 287–305. Thall PF, Fox PS, Wathen JK. Some caveats for outcome adaptive randomization in clinical trials. Modern adaptive randomized clinical trials: statistical and practical aspects: Chapman and Hall/CRC; 2015. p. 287–305.
38.
go back to reference Connor JT, Elm JJ, Broglio KR, Esett, Investigators A-I. Bayesian adaptive trials offer advantages in comparative effectiveness trials: an example in status epilepticus. J Clin Epidemiol. 2013;66(8 Suppl):S130–7.PubMedPubMedCentralCrossRef Connor JT, Elm JJ, Broglio KR, Esett, Investigators A-I. Bayesian adaptive trials offer advantages in comparative effectiveness trials: an example in status epilepticus. J Clin Epidemiol. 2013;66(8 Suppl):S130–7.PubMedPubMedCentralCrossRef
39.
go back to reference Thall P, Fox P, Wathen J. Statistical controversies in clinical research: scientific and ethical problems with adaptive randomization in comparative clinical trials. Ann Oncol. 2015;26(8):1621–8.PubMedPubMedCentralCrossRef Thall P, Fox P, Wathen J. Statistical controversies in clinical research: scientific and ethical problems with adaptive randomization in comparative clinical trials. Ann Oncol. 2015;26(8):1621–8.PubMedPubMedCentralCrossRef
40.
go back to reference Karrison TG, Huo D, Chappell R. A group sequential, response-adaptive design for randomized clinical trials. Control Clin Trials. 2003;24(5):506–22.PubMedCrossRef Karrison TG, Huo D, Chappell R. A group sequential, response-adaptive design for randomized clinical trials. Control Clin Trials. 2003;24(5):506–22.PubMedCrossRef
42.
go back to reference Angus DC, Berry S, Lewis RJ, Al-Beidh F, Arabi Y, van Bentum-Puijk W, et al. The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) study. Rationale and design. Ann Am Thorac Soc. 2020;17(7):879–91.PubMedPubMedCentralCrossRef Angus DC, Berry S, Lewis RJ, Al-Beidh F, Arabi Y, van Bentum-Puijk W, et al. The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) study. Rationale and design. Ann Am Thorac Soc. 2020;17(7):879–91.PubMedPubMedCentralCrossRef
43.
go back to reference Dmitrienko A, D'Agostino RB Sr. Multiplicity considerations in clinical trials. N Engl J Med. 2018;378(22):2115–22.PubMedCrossRef Dmitrienko A, D'Agostino RB Sr. Multiplicity considerations in clinical trials. N Engl J Med. 2018;378(22):2115–22.PubMedCrossRef
44.
go back to reference Ryan EG, Brock K, Gates S, Slade D. Do we need to adjust for interim analyses in a Bayesian adaptive trial design? BMC Med Res Methodol. 2020;20(1):1–9.CrossRef Ryan EG, Brock K, Gates S, Slade D. Do we need to adjust for interim analyses in a Bayesian adaptive trial design? BMC Med Res Methodol. 2020;20(1):1–9.CrossRef
45.
go back to reference Broglio KR, Connor JT, Berry SM. Not too big, not too small: a goldilocks approach to sample size selection. J Biopharm Stat. 2014;24(3):685–705.PubMedCrossRef Broglio KR, Connor JT, Berry SM. Not too big, not too small: a goldilocks approach to sample size selection. J Biopharm Stat. 2014;24(3):685–705.PubMedCrossRef
46.
48.
go back to reference Viele K, Broglio K, McGlothlin A, Saville BR. Comparison of methods for control allocation in multiple arm studies using response adaptive randomization. Clin Trials. 2020;17(1):52–60.PubMedCrossRef Viele K, Broglio K, McGlothlin A, Saville BR. Comparison of methods for control allocation in multiple arm studies using response adaptive randomization. Clin Trials. 2020;17(1):52–60.PubMedCrossRef
49.
go back to reference Korn EL, Freidlin B. Adaptive clinical trials: advantages and disadvantages of various adaptive design elements. J Natl Cancer Inst. 2017;109(6):djx013.PubMedCentralCrossRef Korn EL, Freidlin B. Adaptive clinical trials: advantages and disadvantages of various adaptive design elements. J Natl Cancer Inst. 2017;109(6):djx013.PubMedCentralCrossRef
50.
go back to reference Murray GD, Barer D, Choi S, Fernandes H, Gregson B, Lees KR, et al. Design and analysis of phase III trials with ordered outcome scales: the concept of the sliding dichotomy. J Neurotrauma. 2005;22(5):511–7.PubMedCrossRef Murray GD, Barer D, Choi S, Fernandes H, Gregson B, Lees KR, et al. Design and analysis of phase III trials with ordered outcome scales: the concept of the sliding dichotomy. J Neurotrauma. 2005;22(5):511–7.PubMedCrossRef
51.
go back to reference Saver JL. Optimal end points for acute stroke therapy trials: best ways to measure treatment effects of drugs and devices. Stroke. 2011;42(8):2356–62.PubMedPubMedCentralCrossRef Saver JL. Optimal end points for acute stroke therapy trials: best ways to measure treatment effects of drugs and devices. Stroke. 2011;42(8):2356–62.PubMedPubMedCentralCrossRef
52.
53.
go back to reference de Valpine P, Turek D, Paciorek CJ, Anderson-Bergman C, Lang DT, Bodik R. Programming with models: writing statistical algorithms for general model structures with NIMBLE. J Comput Graphical Stat. 2017;26(2):403–13.CrossRef de Valpine P, Turek D, Paciorek CJ, Anderson-Bergman C, Lang DT, Bodik R. Programming with models: writing statistical algorithms for general model structures with NIMBLE. J Comput Graphical Stat. 2017;26(2):403–13.CrossRef
54.
go back to reference Berry S, Sanil A. FACTSTM Dose finding: single endpoint engine specification. Newton: Tessela; 2010. Berry S, Sanil A. FACTSTM Dose finding: single endpoint engine specification. Newton: Tessela; 2010.
55.
Metadata
Title
Optimizing a Bayesian hierarchical adaptive platform trial design for stroke patients
Authors
Guangyi Gao
Byron J. Gajewski
Jo Wick
Jonathan Beall
Jeffrey L. Saver
Caitlyn Meinzer
the STEP-STONE Executive Committee
Publication date
01-12-2022
Publisher
BioMed Central
Keyword
Stroke
Published in
Trials / Issue 1/2022
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-022-06664-4

Other articles of this Issue 1/2022

Trials 1/2022 Go to the issue